Drugs / LY01610
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04088604 | Feb 2019 → Dec 2021 | neoplasm | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04381910 | Sep 2020 → Mar 2023 | small cell lung carcinoma | Luye Pharma Group Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY01610 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04381910 ↗ |
| Known as | Irinotecan hydrochloride liposome injection | “LY01610 ( Irinotecan hydrochloride liposome injection )” NCT04088604 ↗1“LY01610( Irinotecan hydrochloride liposome injection )” NCT04381910 ↗ |
| Route | Intravenous | “LY01610 was administered intravenously every 2 weeks” PMID 34031756 ↗ May 2021 |